We performed statistical analyses on the correlations between progression free survival (PFS) and the patients' gender, age, BMI, pathological grade, tumor size, lymphatic metastasis, TNM stage, expression of EGFR, COX2, p53, nm23, and EGFR&nm23 combined expression. This evidence concerns the gene TP53 and neoplasm.